These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9789718)

  • 1. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus.
    Kuzuya T; Kosaka K; Akanuma Y; Shigeta Y; Kaneko T
    Diabetes Res Clin Pract; 1998 Aug; 41(2):121-9. PubMed ID: 9789718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
    Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
    Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.
    Kuzuya T; Iwamoto Y; Kosaka K; Takebe K; Yamanouchi T; Kasuga M; Kajinuma H; Akanuma Y; Yoshida S; Shigeta Y
    Diabetes Res Clin Pract; 1991 Mar; 11(3):147-53. PubMed ID: 2036936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.
    Iwamoto Y; Kuzuya T; Matsuda A; Awata T; Kumakura S; Inooka G; Shiraishi I
    Diabetes Care; 1991 Nov; 14(11):1083-6. PubMed ID: 1797492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.
    Foot EA; Eastmond R
    Diabetes Res Clin Pract; 1997 Oct; 38(1):41-51. PubMed ID: 9347245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
    Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of troglitazone on endothelial function in type 2 diabetic patients.
    Takase H; Hakamata M; Toriyama T; Hayashi K; Gotoa T; Sato K; Ueda R; Dohi Y
    Arzneimittelforschung; 2002; 52(1):34-8. PubMed ID: 11838272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
    Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
    Willi SM; Kennedy A; Brant BP; Wallace P; Rogers NL; Garvey WT
    Diabetes Res Clin Pract; 2002 Nov; 58(2):87-96. PubMed ID: 12213349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
    Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y
    Diabetes Care; 1999 Jun; 22(6):908-12. PubMed ID: 10372240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP; Yu JG; Kruszynska YT; Olefsky JM
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
    Ghazzi MN; Perez JE; Antonucci TK; Driscoll JH; Huang SM; Faja BW; Whitcomb RW
    Diabetes; 1997 Mar; 46(3):433-9. PubMed ID: 9032099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
    Prigeon RL; Kahn SE; Porte D
    J Clin Endocrinol Metab; 1998 Mar; 83(3):819-23. PubMed ID: 9506734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.